慢肝合剂治疗慢性病毒性乙型肝炎抗病毒疗效观察及对肝纤维化的改善研究

Antiviral Effect Observation of Mangan Mixture for Chronic Viral Hepatitis B and the Study on the Improvement of Liver Fibrosis

目的:探讨慢肝合剂对慢性病毒性乙型肝炎患者的抗病毒效果以及肝纤维化的影响。方法:将慢性乙型肝炎肝纤维化患者72例按数字表法随机分为观察组和对照组各36例。对照组给予恩替卡韦分散片。观察组在对照组治疗基础上给予慢肝合剂治疗。治疗6个月后,比较2组肝功能、肝纤维化、临床疗效以及乙型肝炎病毒(HBV)标志物及定量。结果:治疗6个月后,2组天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、γ-谷氨酸酰基转移酶(GGT)水平显著降低(P<0.01);且观察组AST、ALT、GGT水平低于对照组(P<0.01)。治疗6个月后,2组透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-C)、层黏蛋白(LN)下降(P<0.01);且观察组各肝纤维化指标低于对照组(P<0.01)。治疗6个月后,观察组总有效率97.22%,高于对照组的80.56%(P<0.05)。治疗6个月后,观察组的乙肝病毒e抗原(HBeAg)、HBV-DNA转阴率均高于对照组(P<0.05)。结论:在常规治疗基础上,结合慢肝合剂可有效改善慢性病毒性乙型肝炎患者的肝功能和肝纤维化,提高临床疗效和抗病毒效果。

Objective: To investigate the antiviral effect of Mangan mixture for patients with chronic viral hepatitis B and the effect on liver fibrosis. Methods:Divided 72 cases of patients with chronic viral hepatitis B liver fibrosis randomly into the observation group and the control group with 36 cases in each group. The control group was given entecavir dispersible tablets, while the observation group was treated with Mangan mixture on the basis of the control group. Compared the liver function, liver fibrosis,clinical effect,hepatitis B virus(HBV) markers and quantification between the two groups after 6 months of treatment. Results:After 6 months of treatment,the levels of aspartate aminotransferase(AST),alanine aminotransferase(ALT),and γ-glutamate acyltransferase(GGT) in the two groups were significantly decreased(P < 0.01);the levels of AST,ALT and GGT in the observation group were lower than those in the control group(P < 0.01). After 6 months of treatment,the hyaluronic acid(HA),type III procollagen(PCIII),type IV collagen(IV-C),laminin(LN) in the two groups were all decreased(P < 0.01);each fibrosis index in the observation group was lower than that in the control group(P < 0.01). After 6 months of treatment, the total effective rate of the observation group was 97.22%,which was higher than that of 80.56% in the control group(P < 0.05). After 6 months of treatment, the hepatitis B virus e antigen(HBeAg) and HBV-DNA negative conversion rate in the observation group were higher than those in the control group(P < 0.05).Conclusion:The combined application of Mangan mixture on the basis of routine treatment can effectively improve liver function and liver fibrosis in patients with chronic viral hepatitis B and promote clinical effect and antiviral effect.